Thus, SPHK1 appears to be a viable target to ameliorate the development of lung fibrosis in preclinical models; however, clinical trials to determine the efficacy of SPHK1 inhibitor(s) in treating IPF are required. Here, SPHK1 is linked to pulmonary fibrosis.